A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 Mcg of Env 2-3 in MF59 - Contacts and Locations

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 Mcg of Env 2-3 in MF59

This study has been completed.

Study NCT00000632. Last updated on June 23, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000632

Locations


United States, New York
	Univ of Rochester Med Ctr
	Rochester, New York, United States, 14642

United States, Tennessee
	Vanderbilt Univ Hosp
	Nashville, Tennessee, United States, 37232

United States, Washington
	Children's Hospital & Medical Center / Seattle ACTU
	Seattle, Washington, United States, 981050371

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Biocine

Investigators


Study Chair:	Dolin R